Hämostaseologie, Table of Contents Hamostaseologie 1986; 06(02): 89-92DOI: 10.1055/s-0038-1655142 Originalarbeiten Schattauer GmbH Erworbene Antikörper gegen Gerinnungsfaktoren I. Scharrer Recommend Article Abstract Buy Article Full Text References LITERATUR 1 Al-Ismail S A D, Parry D H, Moisey C U, Bloom A L. Factor VIII inhibitor and bronchogenic carcinoma. Thromb Haemost. 1979; 41: 291. 2 Allain J P, Gaillandre A, Frommei D. Acquired hemophilia: Functional study of antibodies to factor VIII. Thromb Haemost. 1981; 45: 285. 3 Amblard P, Reymond J L, Beani J C. Anticoagulants acquis d’origine immunologique: Association d’une pemphigoide localisée et d’un anticoagulant anti-facteur-VIII. Nouvelle Presse Med. 1981; 31: 2484-585. 4 Brackmann H H. Treatment of Hemophilia Patients with Inhibitor against F. VIII. In: Scharrer I, Breddin K. (eds). Hämostase und Atherosklerose bei Hämophilie und von-Willebrand-Syndrom. Schattauer: Stuttgart; 1981: 123-39. 5 Deutsch E. Über eine eigentümliche hämorrhagische Diathese: die Hemmkörper-hämophilie. Klin Wschr. 1950; 28: 326. 6 Fasching I, Lechner K, Bettelheirn P. Variable response to high dose factor VIII treatment in hemophiliacs with antibody to factor VIII. In: Blombäck M. Proc Congr WFH, Stockholm; Karger, Basel: 1983 7 Feinstein D I. Acquired inhibitors of factor V. Thromb Haemost. 1978; 39: 663. 8 Gianella-Borradori A, Hirt A, Liithy A, Wagner H P, Imbach P. Hemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease: treatment with intravenous immunoglobulin. Blut. 1984; 48: 403-7. 9 Green D. Spontaneous inhibitors of factor VIII. Br J Haematol. 1968; 15: 57. 10 Green D, Lechner K. A survey of 215 nonhemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981; 45: 200. 11 Handin R J, Moloney W C. Antibody-induced von Willebrand’s disease. Blood 1974; 44: 933. 12 Kasper C K, Aledort L M, Counts R E. A more uniform measurement of factor VIII inhibitor. Thromb Diathes Haemorrh. 1975; 34: 869. 13 Kasper C K, Ewing N P. Measurement of inhibitor to factor VIIIC (and IXC). In: Bloom A L. (ed). The Hemophilias, Methods in Hematology, 5. Churchill Livingstone. 1982: 39-50. 14 Kowalski E. Fibrinogen derivatives and their biologic activities. Thromb Diath Haemorrh 1963; 10: 406. 15 Kreuz W, Scharrer I. Elimination of factor VIII inhibitors in 6 children with severe hemophilia A. Abstract 178, XVI Internat. Congr of WFH, Rio de Janeiro. 1984 16 Lechner K. Acquired inhibitors in non-haemophilic patients. Haemost. 1974; 03: 65. 17 Lechner K. Acquired inhibitors in iso-and auto-immune disease. Thromb Diath Haemorrh. 1971; (Suppl) 45: 227. 18 Lechner K, Krinninger B. Immunkoagulo-pathien Pathogenese, Diagnostik und Therapie. In: Heene D L. (ed). Immunologische Probleme in der Blutgerinnung, von-Wille-brand-Syndrom. Schattauer; Stuttgart, New York: 1978: 78. 19 Lechner K. Blutgerinnungsstörungen. Springer, Heidelberg; 1982 20 Lechner K. Immunkoagulopathien. In: Heene D L. (ed). Handbuch der Inneren Medizin. Blut und Blutkrankheiten, Teil 9, Blutgerinnung und hämorrhagische Diathe-sen. Springer, Heidelberg; 1985: 636 21 Lewis J H. Hemorrhagic disease associated with inhibitors of fibrin cross-linkage. Ann NY Acad Sci. 1972; 202: 213. 22 Mammen E F, Schmidt K P, Barnhart M I. Thrombophlebitis migrans associated with circulating antibodies against fibrinogen. Thromb Diath Haemorrh. 1967; 18: 605. 23 Michiels J J, Bosch L J, van der Pias P M, Abels J. Factor VIII inhibitor postpartum. Scand J Haematol. 1978; 20: 97. 24 McMillan C W. Clinical patterns of hemophilic patients who develop inhibitors. In: Hoyer L W. (ed). Factor VIII inhibitors. Alan R Riss; New York: 1984 25 Niessner H. Das erworbene von-Willebrand-Jürgens-Syndrom. In: Scharrer I, Breddin K. (eds). Haemostase und Atherosklerose bei Hämophilie und von-Willebrand-Syndrom. Schattauer, Stuttgart; 1981 26 Nilsson I M, Sundqvist S B, Ljung R, Holmberg L, Freiburghaus C, Björlin G. Suppression of secondary antibody response by intravenous immunoglobulin in a patient with hemophilia B and antibodies. Scand J Haematol. 1983; 30: 458-64. 27 Raz I, Rimon A, Lahay M. Inhibition of blood coagulation factor XI-XII by monoclonal IgM. Isr J Med Sci. 1975; 11: 1392 (Abstract). 28 Rizza C R, Biggs R. The treatment of patients who have factor VIII antibodies. Brit J Haematol. 1973; 24: 65-82. 29 Scharrer I. Ergebnisse der kombinierten Hochdosisbehandlung mit einem modifizierten Bonner Therapiekonzept bei 3 erwachsenen Patienten mit Hemmkörper-hämophilie. 14. Hamburger Hämophiliesymposion. 1984. Schattauer, Stuttgart; (in Druck). 30 Scharrer I. Comparison of immunosuppressive-, corticosteroid-and IgG treatment of an acquired factor VIII inhibitor. Abstract S 39, Bari internat, conference on factor-VIII/ von Willebrand factor. Bari. June, 1985. Org. by Ciavarella.. 31 Shapiro S S, Hultin M. Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost. 1975; 01: 336. 32 Shapiro S S, Thiagarajan P. Lupus anticoagulants. In: Spalt Th H. 1982; 06: 263-85. 33 Sjamsoedin L J M, Heijen L, Mauser-Bunschoten E P, van Geijlswijk J L, van Houwelingen H, van Asten P, Sixma J J. The effect of an activated prothrombincom-plex concentrate (Feiba) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A doubleblind clinical trial. N Engl J Med. 1981; 305: 717-21. 34 Stenbjerg S, Husted S, Mygind K. A circulating factor V inhibitor: possible side effect of treatment with streptomycin. Scand J Haematol. 1975; 14: 280. 35 Stenbjerg S, Jorgensen J, Tauris P, Skottun T. Low dose factor VIII for the treatment of hemophilia with inhibitors. In: Mariani G, Russo M A, Mandelli F. (eds). Activated Prothrombin Complex Concentrates. Prae-ger, New York; 1982: 206-12. 36 Sultan Y, Maisonneuve P, Kazatchkine M D, Nydegger U E. Anti-idiotypic suppression of auto antibodies to factor VIII (antihemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; II: 765-8. 37 Waddell C C, Lehane D E, Zubler M A. Acquired factor VIII inhibitor in a patient with mycosis fungoides. Cancer 1981; 47: 2901. 38 Wautier J-L, Levy S, Caen J P. Acquired von Willebrand syndrome with inhibitors both to Factor VIII clotting activity and ristocetin-induced platelet aggregation. Br J Haematol. 1976; 33: 565. 39 Zimmermann R, Kommereil B, Harenberg J, Eich W, Rother K, Schimpf K. Intravenous IgG for patients with spontaneous inhibitor to factor VIII. Lancet. 1985: 273-4.
